<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504867</url>
  </required_header>
  <id_info>
    <org_study_id>10-004856</org_study_id>
    <secondary_id>U01HL108712-01</secondary_id>
    <secondary_id>KL2RR024151</secondary_id>
    <secondary_id>K23HL112855</secondary_id>
    <secondary_id>UL1TR000433</secondary_id>
    <nct_id>NCT01504867</nct_id>
  </id_info>
  <brief_title>LIPS-A: Lung Injury Prevention Study With Aspirin</brief_title>
  <official_title>LIPS-A: Lung Injury Prevention Study With Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis was that early aspirin administration will decrease the rate of
      developing acute lung injury during the first 7 days after presentation to the hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory distress syndrome (ARDS) remains a life-threatening critical care syndrome
      characterized by alveolar-capillary membrane injury and hypoxemic respiratory failure. The
      median time to onset of ARDS is 2 days after hospital presentation. Therefore, the period
      between hospital presentation and the development of ARDS presents a brief window of
      opportunity for ARDS prevention.

      This was a multicenter, double-blind, placebo-controlled, parallel-group, Phase 2b,
      randomized clinical trial. Development of ARDS was defined by Berlin criteria (modified to
      require invasive mechanical ventilation) within 7 days of hospital admission. The first dose
      of study drug or placebo was administered within 24 hours after presentation to the hospital.
      Important co-interventions were standardized across sites using a web-based tool, Checklist
      for Lung Injury Prevention. Study participants were screened daily for receipt of mechanical
      ventilation and determination of the partial pressure of arterial oxygen (PaO2) or oxygen
      saturation to fraction of inspired oxygen ratio (SpO2:FIO2). If the participant's SpO2:FIO2
      ratio was consistently below 315, hypoxemia was confirmed with measurement of arterial blood
      gas. Chest radiographs for all intubated patients with a SpO2:FIO2 of 300 or less were
      independently reviewed by both site investigator and a member of the trial's executive
      committee. Study participants who died or were discharged from the hospital before day 7
      without meeting criteria for ARDS were adjudicated as not having ARDS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days</measure>
    <time_frame>Within seven days from hospital presentation</time_frame>
    <description>ARDS was defined by Berlin criteria (modified to require invasive mechanical ventilation) within 7 days of hospital admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ARDS or Mortality Within 7 Days</measure>
    <time_frame>within 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Mechanical Ventilation at Any Time During Hospitalization</measure>
    <time_frame>approximately 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days Participants Were Ventilator-Free To Day 28</measure>
    <time_frame>baseline, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Admitted to Intensive Care Unit (ICU)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hospital Length of Stay</measure>
    <time_frame>approximately 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group received matching lactose powder filled capsules on days 1-7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose powder</intervention_name>
    <description>Matching lactose powder filled capsules will be administered on days 1-7.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt; 18) admitted to the hospital through the emergency department
             (ED)

          -  At high risk of developing acute lung injury (ALI) Lung Injury Prediction Score (LIPS)
             greater than or equal to 4

        Exclusion Criteria:

          -  Anti-platelet therapy on admission or within 7 days prior to admission

          -  Presented to outside hospital ED &gt; 12 hrs before arrival at site's facility

          -  Inability to obtain consent within 12 hours of hospital presentation

          -  Admitted for elective surgery

          -  Acute lung injury prior to randomization

          -  Receiving mechanical ventilation through a tracheostomy tube prior to current hospital
             admission (patient who is ventilator dependent)

          -  Presence of bilateral pulmonary infiltrates on admission if he or she has a history of
             bilateral pulmonary infiltrates (as evidenced by previous x-rays) that can reasonably
             explain the current degree of pulmonary infiltrates present.

          -  Presentation due to pure heart failure and no other known risk factors for ALI.

          -  Allergy to aspirin or non steroidal anti inflammatory drugs (NSAIDs)

          -  Bleeding disorder

          -  Suspected active bleeding or judged to be at high risk for bleeding

          -  Active peptic ulcer disease (within past 6 months)

          -  Severe chronic liver disease

          -  Inability to administer the study drug

          -  Expected hospital stay &lt; 48 hours

          -  Admitted for comfort or hospice care

          -  Patient, surrogate or physician not committed to full support. (Exception: a patient
             will not be excluded if he/she would receive all supportive care except for attempts
             at resuscitation from cardiac arrest)

          -  Not anticipated to survive &gt; 48 hours

          -  Previously enrolled in this trial

          -  Enrolled in a concomitant intervention trial

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl Kor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Univeristy</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kor DJ, Carter RE, Park PK, Festic E, Banner-Goodspeed VM, Hinds R, Talmor D, Gajic O, Ware LB, Gong MN; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A). Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. JAMA. 2016 Jun 14;315(22):2406-14. doi: 10.1001/jama.2016.6330. Erratum in: JAMA. 2016 Sep 13;316(10):1116.</citation>
    <PMID>27179988</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>August 17, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2016</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Daryl J. Kor, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Acute Lung Injury</keyword>
  <keyword>ARDS</keyword>
  <keyword>ALI</keyword>
  <keyword>aspirin</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between 1/2/2012 and 11/17/2014 at multiple US academic hospitals.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin</title>
          <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>This group received matching lactose powder filled capsules on days 1-7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent revoked</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>400 subjects were randomized, and 10 subjects were excluded, leaving 390 in the final modified intention-to-treat analysis cohort.</population>
      <group_list>
        <group group_id="B1">
          <title>Aspirin</title>
          <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>This group received matching lactose powder filled capsules on days 1-7.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" lower_limit="44.0" upper_limit="67.0"/>
                    <measurement group_id="B2" value="57.0" lower_limit="47.0" upper_limit="68.0"/>
                    <measurement group_id="B3" value="57" lower_limit="45" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days</title>
        <description>ARDS was defined by Berlin criteria (modified to require invasive mechanical ventilation) within 7 days of hospital admission.</description>
        <time_frame>Within seven days from hospital presentation</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days</title>
          <description>ARDS was defined by Berlin criteria (modified to require invasive mechanical ventilation) within 7 days of hospital admission.</description>
          <population>Intention-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary outcome significance level was adjusted for multiple testing associated with the interim analysis. Its significance level is 92.6%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Wald</method>
            <method_desc>This was a large sample (Wald) test estimated using a conditional logistic regression model with site as a stratification variable.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality</title>
        <time_frame>28 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <population>Intention-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ARDS or Mortality Within 7 Days</title>
        <time_frame>within 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ARDS or Mortality Within 7 Days</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Mechanical Ventilation at Any Time During Hospitalization</title>
        <time_frame>approximately 7 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Mechanical Ventilation at Any Time During Hospitalization</title>
          <population>Intention-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days Participants Were Ventilator-Free To Day 28</title>
        <time_frame>baseline, Day 28</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days Participants Were Ventilator-Free To Day 28</title>
          <population>Intention-to-Treat</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="7.4"/>
                    <measurement group_id="O2" value="25.2" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Admitted to Intensive Care Unit (ICU)</title>
        <time_frame>7 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Admitted to Intensive Care Unit (ICU)</title>
          <population>Intention-to-Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hospital Length of Stay</title>
        <time_frame>approximately 7 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This group received matching lactose powder filled capsules on days 1-7.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hospital Length of Stay</title>
          <population>Intention-to-Treat</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="10.3"/>
                    <measurement group_id="O2" value="9.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>This group received matching lactose powder filled capsules on days 1-7.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Anemia due to Upper GI Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding Stress Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia/Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Cerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Mild Indigestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Renal Failure Requiring Dialysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Right Hip Resection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Nose Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daryl J. Kor</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-7678</phone>
      <email>Kor.Daryl@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

